Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 1266

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 8
Chunk 1266
---
  
     2,005,779 
  
    Less: accumulated depreciation 
     (978,889) 
     (990,550)
  
    Fixed assets, net 
    $676,220  
    $1,015,229 

     F-15 

Depreciation expense for the fiscal years ended March 31, 2025 and
2024 was $339,009 and $358,507, respectively. During the year ended March 31, 2025, the Company disposed of fully depreciated property
and equipment with an original cost of $350,670. These disposals had no impact on net income, as the assets were fully depreciated
at the time of removal. The reduction in gross property and equipment reflects the Company’s ongoing review and retirement of inactive
or obsolete assets.

3. PATENTS, NET

Patents, net consist of the following:

    Schedule of patents, net 

    March 31, 2025  
    March 31, 2024 
  
    Issued patents 
    $157,442  
    $157,442 
  
    Accumulated amortization 
     (156,892) 
     (156,342)
  
    Patents, net 
    $550  
    $1,100 

Amortization expense for our capitalized issued
patents for each of the fiscal years ended March 31, 2025 and 2024 was $550. As only one capitalized patent remains to be amortized, future
amortization expense on patents is estimated to be approximately $550 per year based on the estimated life of the patent. The weighted
average remaining life of our remaining capitalized patent is approximately 1.0 year.

4. EQUITY TRANSACTIONS

REVERSE
STOCK SPLIT

Effective as of
the close of business on June 6, 2025 with an effective trading date of  June 9, 2025, we
effected a 1-for-8 reverse
stock split of our then outstanding shares of common stock. Accordingly, each 8 shares of outstanding common stock then held by our
stockholders were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded up to
the next whole share. Authorized common stock remained at 60,000,000 shares
following the stock split. The accompanying consolidated financial statements and accompanying notes have been retro